Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Neumora Therapeutics, Inc., with ticker symbol NMRA, is a clinical-stage biopharmaceutical company operating in the neuroscience sector. The company is dedicated to addressing the global brain disease crisis by developing innovative treatments for a wide range of neuropsychiatric disorders and neurodegenerative diseases.

Neumora's primary business activities involve the research, development, and commercialization of novel neuroscience therapeutics. The company operates in the United States and leverages its proprietary data science and translational neuroscience tools, known as the Precision Toolbox, to enhance its development efforts. The Precision Toolbox consists of approximately 1 petabyte of longitudinal, multimodal patient data, including genetic, imaging, EEG, digital, and clinical data across various neuropsychiatric disorders and neurodegenerative diseases.

Neumora generates revenue through the development of various product candidates, each targeting novel mechanisms of action for specific brain diseases. Its most advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD). Navacaprant has shown positive results in a Phase 2 clinical trial, demonstrating statistically significant treatment differences compared to placebo in depression and anhedonia in patients with moderate to severe MDD.

Another prominent product candidate in Neumora's pipeline is NMRA-266, a positive allosteric modulator of the M4 muscarinic receptor (M4R) being developed for the treatment of schizophrenia. The company has initiated a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study in healthy adult participants and plans to initiate a Phase 1b study with NMRA-266 in adults with schizophrenia in the second half of 2024.

Neumora's competitive advantage lies in its focus on novel mechanisms of action and its Precision Toolbox approach, which has the potential to deliver improved treatment outcomes and quality of life for patients suffering from neuropsychiatric disorders and neurodegenerative diseases. The company's intellectual property estate, including composition of matter patents for each program, provides sufficient runway to enable clinical trials in multiple indications.

In terms of customers, Neumora primarily serves patients suffering from neuropsychiatric disorders and neurodegenerative diseases, as well as healthcare providers and research institutions.

The Precision Toolbox Patent Portfolio includes several patent families, with seven issued U.S. patents and additional pending U.S. and foreign patent applications. These patents are expected to expire between 2038 and 2044, excluding any patent term adjustment. Neumora also relies on trade secrets, know-how, confidentiality agreements, and continuing technological innovation to develop and maintain its competitive position.

Neumora's biomarker patent portfolio consists of six patent applications relating to unimodal and multimodal biomarkers that identify patients who respond to specific drugs. These biomarker patents are process patents for identifying and diagnosing patients with selected biomarkers and methods of treating patients with those biomarkers with neural drugs.

In addition to its patent and trademark protections, Neumora has entered into research collaboration agreements with Amgen and Vanderbilt University to discover drug targets, biomarkers, and other insights associated with CNS diseases and small molecule positive allosteric modulators of the muscarinic acetylcholine receptor subtype 4 (M4), respectively.